Guardant360® TissueNext™
Tissue-based comprehensive genomic profiling with digital pathology
Guardant360® TissueNext™ is a multiomic test for patients with advanced solid tumors, providing comprehensive genomic, transcriptomic, and epigenomic insights using minimal tissue—requiring 92% less surface area and 40% fewer slides than the industry standard.
Source: https://www.guardanthealthamea.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/
Oncologists requiring tissue-based comprehensive genomic profiling, or when tissue-ctDNA concordance is needed.
740+ DNA Genes, 360+ RNA fusions, 19,000+ epigenomic signals, MSI, TMB, PD-L1
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | ≥95% | |
| Specificity | ≥98.9% |
FFPE tumour tissue block or 8 unstained slides (NGS + PDL1). Minimum 2mm² surface area. Minimum 5% Tumour Content.
- Submit FFPE block or 8 unstained slides (5 μm) with H&E slide for pathology review. Recommended tumor cellularity ≥20%
- Additional slides are required for optional IHC tests.
Samples must be submitted through an authorised healthcare provider.
- Submit FFPE block or 8 unstained slides (5 μm) with H&E slide for pathology review.
- Label clearly with patient ID, accession number, and collection date.
- Wrap slides in tissue paper; ship in a rigid protective container.
- Include pathology report and completed test requisition form. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
Guardant360 TissueNext identifies clinically relevant actionable biomarkers in tumor tissue to help oncologists select patients with advanced cancer who may benefit from biomarker-informed treatment. Results are provided in about two working weeks.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
